Fiche centre
MedStar Washington Hospital Center
Washington D.C. — United States
Essais liés13clinical trials
VilleWashington D.C.localisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05069558
Essais cliniques associés
13| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Selatogrel | Maladie coronarienne | Phase 3 | NCT04957719 | SOS-AMI — Selatogrel Outcome Study in Suspected Acute Myocardial Infarction | ENROLLING_BY_INVITATION |
| Arctic Front™ Cardiac Cryoablation Catheter | Maladie coronarienne | À vérifier | NCT05227053 | STOP AF First Post-Approval Study | COMPLETED |
| Bevacizumab | Cancer | Phase 3 | NCT07198074 | Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer | RECRUITING |
| SESAME Procedure | Maladie coronarienne | Non applicable | NCT07806149 | NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices | NOT_YET_RECRUITING |
| Investigational PFO Closure Device | Accident vasculaire cérébral | Non applicable | NCT05069558 | OCCLUFLEX — Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion | ACTIVE_NOT_RECRUITING |
| Ribociclib | Cancer | Phase 3 | NCT05827081 | Adjuvant WIDER — Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | RECRUITING |
| Biopsy Procedure | Cancer | Phase 2/3 | NCT04628767 | Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | RECRUITING |
| Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated | Hypertension | Non applicable | NCT06059638 | BACKBEAT — BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT04267848 | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | RECRUITING |
| Remibrutinib (Blinded) | Myasthénie | Phase 3 | NCT06744920 | RELIEVE — A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Ofatumumab approved dose | SEP | Phase 3 | NCT06869785 | FILIOS — Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab | ACTIVE_NOT_RECRUITING |
| Remibrutinib oral treatment | SEP | Phase 3 | NCT06846281 | Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | RECRUITING |
| Renal Denervation (Symplicity Spyral™) | Hypertension | Non applicable | NCT05198674 | SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN | ACTIVE_NOT_RECRUITING |